Welcome to the Bayer
Hemophilia Treatment Hub
Here to help you
Explore our products and resources for advancing hemophilia care
Breaking boundaries
Bayer in hemophilia
Bayer has over 30 years of research and development in hemophilia, exemplified best by our portfolio of recombinant FVIII therapies, which include Kogenate FS/Bayer, Kovaltry, and Jivi.
Besides improving FVIII replacement therapy, Bayer is also pursuing alternative treatment approaches in hemophilia, including gene therapy.
